Prognostic Factors in Laryngeal Squamous Cell Carcinoma Treated with Curative Radiotherapy: A Retrospective Study
Prognostic determinants of survival in laryngeal cancer after curative radiotherapy
DOI:
https://doi.org/10.5281/zenodo.20931458Keywords:
Laryngeal cancer;, Radiotherapy;, Overall survival, Disease-free survival, Prognostic factorsAbstract
Aim: To evaluate overall survival (OS), disease-free survival (DFS), and prognostic clinicopathological factors in patients with laryngeal squamous cell carcinoma treated with curative-intent radiotherapy.
Methods: This retrospective study included 95 patients with laryngeal squamous cell carcinoma treated with curative-intent radiotherapy. OS and DFS were analyzed using the Kaplan–Meier method. Restricted mean survival time (RMST) values were calculated at 24 and 60 months. Factors associated with survival were evaluated by univariate analysis, and variables with statistical significance were further assessed using multivariable Cox regression analysis.
Results: Median follow-up was 56.7 months by the reverse Kaplan–Meier method. During follow-up, 43 deaths and 44 DFS events were observed. Median OS was 69.2 months (95% CI, 50.3–88.1), and the 2- and 5-year OS rates were 71.2% and 55.8%, respectively. Median DFS was 71.0 months (95% CI, 29.5–112.5), with 2- and 5-year DFS rates of 62.5% and 50.2%, respectively. In univariate analyses, lymph node involvement was associated with worse OS and showed borderline significance for DFS. Anterior commissure involvement was significantly associated with shorter DFS, while tumor differentiation was associated with OS. In multivariable Cox regression analysis, lymph node involvement remained an independent prognostic factor for both OS and DFS, whereas anterior commissure involvement remained independently associated with DFS.
Conclusion: Lymph node involvement was the main prognostic factor for both OS and DFS in patients with laryngeal squamous cell carcinoma treated with curative-intent radiotherapy. Anterior commissure involvement was also associated with recurrence risk and may be useful in follow-up planning.
Downloads
References
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
2. Forastiere AA, Weber RS, Trotti A. Organ Preservation for Advanced Larynx Cancer: Issues and Outcomes. Journal of Clinical Oncology. 2015;33(29):3262-3268. doi:10.1200/JCO.2015.61.2978
3. Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020;31(11):1462-1475. doi:10.1016/j.annonc.2020.07.011
4. Elicin O, Giger R. Comparison of Current Surgical and Non-Surgical Treatment Strategies for Early and Locally Advanced Stage Glottic Laryngeal Cancer and Their Outcome. Cancers (Basel). 2020;12(3):732. doi:10.3390/cancers12030732
5. Rao KN, Pai PS, Dange P, et al. Survival Outcomes in T3 Laryngeal Cancers: Primary Total Laryngectomy vs. Concurrent Chemoradiation or Radiation Therapy—A Meta-Analysis. Biomedicines. 2023;11(8):2128. doi:10.3390/biomedicines11082128
6. Steuer CE, El‐Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin. 2017;67(1):31-50. doi:10.3322/caac.21386
7. O’Neill CB, O’Neill JP, Atoria CL, et al. Treatment complications and survival in advanced laryngeal cancer: A population-based analysis. Laryngoscope. 2014;124(12):2707-2713. doi:10.1002/lary.24658
8. Grover S, Swisher-McClure S, Mitra N, et al. Total Laryngectomy Versus Larynx Preservation for T4a Larynx Cancer: Patterns of Care and Survival Outcomes. International Journal of Radiation Oncology*Biology*Physics. 2015;92(3):594-601. doi:10.1016/j.ijrobp.2015.03.004
9. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010;17(6):1471-1474. doi:10.1245/s10434-010-0985-4
10. Bernasconi M, Bilic A, Kauke-Navarro M, Safi AF. Nodal tumor volume as a prognostic factor for oral squamous cell carcinoma—a systematic review. Frontiers in Oral Health. 2023;4. doi:10.3389/froh.2023.1229931
11. Coca-Pelaz A, Hanna EY, Guntinas-Lichius O, et al. Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma: Evolving Prognostic Markers, Molecular Insights, and Implications for Precision Staging. Diagnostics. 2026;16(6):855. doi:10.3390/diagnostics16060855
12. Mannelli G, Comini LV, Santoro R, et al. T1 Glottic Cancer: Does Anterior Commissure Involvement Worsen Prognosis? Cancers (Basel). 2020;12(6):1485. doi:10.3390/cancers12061485
13. Nachalon Y, Reicher Y, Alkan U, Levi L, Bachar G, Popovtzer A. Prognostic factors for survival and nonfunctional larynx in patients with squamous cell carcinoma of the larynx. Laryngoscope. 2020;130(5):1202-1205. doi:10.1002/lary.28173
14. Szturz P, Vermorken JB. Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. Oral Oncol. 2020;101:104492. doi:10.1016/j.oraloncology.2019.104492
15. Tao ZY, Chu G, Su YX. The Prognostic Role of Perineural Invasion for Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2024;16(14):2514. doi:10.3390/cancers16142514
16. Krishnamurthy S, Ahmed I, Vinchurkar K, et al. Lympho-vascular invasion in oral cavity cancers – A bridge between tumour biology and clinical outcomes. Oral Oncology Reports. 2024;11:100477. doi:10.1016/j.oor.2024.100477
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Özgür Yıldırım, Seyit Burhanedtin Zincircioglu
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
